Characteristic Study ID	Intervention(s) and control(s)	Deaths [N]	All adverse events [N / %]	Serious adverse events [N / %]	Left study due to adverse events [N / %]	Hospitalisation [N / %]	Outpatient treatment [N / %]	Symptoms [N / %]
Auvichayapat 2008	I1:   green tea extract C1: placebo	I1: 0 C1: 0 T: 0	‐	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	‐	‐	‐
Diepvens 2005	I1: green tea C1: placebo	I1: 0 C1: 0 T: 0	‐	‐	I1: 0 C1: 0 T: 0	‐	‐	‐
Hill 2007	I1: green tea extract C1: placebo	‐	I1: ‐ (Liver function measurements indicated no adverse effects of treatment, however this info is incomplete) C1: ‐	‐	‐	‐	‐	‐
Hsu 2008	I1: green tea extract C1:  placebo	I1: 0 C1: 0 T: 0	I1: 5 C1: 3 T: 8	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 1a C1: 0 T: 1	‐	I1: 4 C1: 1 T: 5
Hursel 2009	I1: green tea‐caffeine mixture + AP diet I2: green tea‐caffeine mixture + HP diet C1: placebo + AP diet C2: placebo + HP diet	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	‐	‐	‐
Kajimoto 2005	I1: catechin drink – low dose group I2: catechin drink – high dose group C1: placebo drink	‐	I1: 17 I2: 11 C1: 17 T: 45	‐	‐	‐	‐	‐
Kataoka 2004	I1: catechin beverage 278 mg I2: catechin beverage 570 mg: I3: catechin beverage 845 mg C1: control beverage	I1: 0 I2: 0 I3: 0 C1: 0 T: 0	I1: 0 I2: 0 I3: 0 C1: 0 T: 0	I1: 0 I2: 0 I3: 0 C1: 0 T: 0	I1: 0 I2: 0 I3: 0 C1: 0 T: 0	‐	‐	‐
Kovacs 2004	I1: green tea C1: placebo	I1: 0 C1: 0 T: 0	‐	‐	I1: 0 C1: 0 T: 0	‐	‐	‐
Kozuma 2005	I1: catechin beverage C1: placebo beverage	‐		I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	‐	‐	‐
Maki  2009	I1: green tea beverage C1: control beverage	‐	I1: 67% C1: 71% T: ‐	I1: 2 / 3% (tooth disorder, and elevated blood pressure) C1: 1 / 1.6% (tachycardia) T: 3 of 128 / 2.3%	I1: 1 / 1.5% C1: 0 T: 1/128 (0.8%)	I1: 1 / 1.5% C1: 0 T: 1 / 0.8%	‐	‐
Nagao 2007	I1: brewed green tea beverage with added catechins C1: brewed green tea beverage with no added catechins	‐	I1: 0 C1: ‐ T: ‐	I1: 0 C1: ‐ T: ‐	I1: 0 C1: ‐ T: ‐	‐	‐	‐
Suzuki 2009	I1: tea catechin C1: placebo	‐	I1: 9 C1: 1 T: 10	‐	‐	‐	‐	‐
Takase 2008	I1: catechin beverage C1: placebo beverage	‐	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	‐	‐	‐
Takashima 2004	I1: catechin beverage C1: control beverage	I1: 0 C1: 0 T: 0	‐	‐	I1: 0 C1: 0 T: 0	‐	‐	‐
Takeshita 2008	I1: catechin beverage C1: placebo beverage	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	‐	‐	‐
Tsuchida 2010	I1: catechin beverage C1: control beverage	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	I1: 0 C1: 0 T: 0	‐	‐	‐
Wang 2010	I1: GT1 I2: GT2 I3: GT3 C1: C	‐	I1: 0 I2: 0 I3: 0 C1: 0 T: 0	I1: 0 I2: 0 I3: 0 C1: 0 T: 0	I1: 0 I2: 0 I3: 0 C1: 0 T: 0	‐	‐	‐
Westerterp‐ Plantenga 2005	I1: green tea‐caffeine capsule ‐ low habitual caffeine consumers I2: green tea‐caffeine capsule ‐ high habitual caffeine consumers C1: placebo ‐ low habitual caffeine consumers C2: placebo ‐ high habitual caffeine consumers	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	I1: 0 I2: 0 C1: 0 C2: 0 T: 0	‐	‐	‐
Footnotes "‐" denotes not reported aOne participant was hospitalised but it is not clear if this was related to treatment and did not complete study AP: adequate protein; C: control; GT: green tea; HP: high protein; I: intervention; T: total